跨亚型的肉瘤干细胞的遗传和表观遗传特征识别了EZH2作为治疗点
Edmond O'Donnell1, Maria Muñoz2, Ryan Davis3
1Department of Orthopedic Surgery, University of California Davis, Sacramento, CA, 95817, USA.
NPJ precision oncology
|January 9, 2025
概括
软组织肉瘤癌干细胞 (STS-CSCs) 驱动了多克索鲁比辛的耐药性. 用tazemetostat针对EZH2 (增强Zeste同源2) 减少了STS-CSC种群,提供了一个潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 高度软组织肉瘤 (STS) 是一种具有攻击性癌症,结果不佳,通常与化疗耐药性有关.
- 抗环素化疗是STS的标准一线治疗方法,但耐药性显著影响患者的预后.
- 软组织肉瘤癌干细胞 (STS-CSCs) 与治疗耐药性有关.
研究的目的:
- 调查STS-CSCs在多克索鲁比耐药性的作用.
- 识别不同STS亚型中常见的遗传或表观遗传脆弱性,可以用于治疗.
- 评估EZH2作为STS-CSC中的潜在治疗标.
主要方法:
- 对STS-CSC丰度与多克索鲁比IC50值的相关性分析.
- 分析了来自五种类型的患者抽取的样本,以确定共同的遗传特征.
- 评估Zeste同类2 (EZH2) 增强剂在STS-CSC中的丰富和活性.
- 在体外治疗耐多克索鲁比细胞系的tazemetostat,一个EZH2抑制剂.
主要成果:
- 在STS-CSC丰富度和多克索鲁比耐药性 (IC50) 之间发现了正相关性.
- 聚抑制复合体2 (PRC2) 的组成部分EZH2在多种类型的瘤亚型中得到了STS-CSC的丰富.
- 使用tazemetostat针对EZH2导致STS-CSC种群的显著减少.
- 在STS-CSC中确定了与EZH2相关的共享表观遗传特征.
结论:
- STS-CSCs在高等级软组织瘤中对多克索鲁比辛耐药性有显著的贡献.
- EZH2代表了在各种STS亚型中共同的,可针对性的漏洞.
- 正如tazemetostat所证明的那样,EZH2的抑制有效地减少了STS-CSC群体,这表明了一个有前途的治疗途径.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K


